Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ADME and pharmacokinetics study of [14C]ganaplacide in healthy men
NL-OMON51536Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ganaplacide in malaria, sponsored by Novartis. Primary endpoints: Routes and rates of excretion and mass balance, Pharmacokinetics of total radiolabeled components in blood and plasma and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
ganaplacide
03
Conditions
malaria
Beyond the preview
Go deeper on NL-OMON51536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51536.